<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518115</url>
  </required_header>
  <id_info>
    <org_study_id>GLP110125</org_study_id>
    <nct_id>NCT00518115</nct_id>
  </id_info>
  <brief_title>Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only</brief_title>
  <official_title>A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are
      either taking no diabetes medication or who are taking metformin only. This study will
      investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will
      measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16
      weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide
      (GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up
      visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring
      of any side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 16-week, parallel-group, double-blind, randomized, placebo-controlled, multicenter,
      dose-ranging study to evaluate the efficacy, safety and tolerability of multiple doses and
      multiple treatment regimens of Albiglutide (GSK716155) with Byetta as an open-label active
      reference, in subjects with Type 2 Diabetes Mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</measure>
    <time_frame>Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
    <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Target Values for HbA1c &lt;6.5% and &gt;=6.5% to &lt;7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</measure>
    <time_frame>Weeks (W) 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
    <description>The number of participants who achieved target values for HbA1c (i.e., HbA1c &lt;6.5% and &gt;=6.5% to &lt;7%) were assessed. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in waist circumference was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. Percent change from Baseline was calculated as the ([value at Week 16 minus the Baseline value] divided by the Baseline value) multiplied by 100. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</measure>
    <time_frame>Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
    <description>The FPG test measures blood sugar levels after the participant has not eaten (fasted) for at least eight hours prior to the sampling. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FPG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16</measure>
    <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
    <description>Fasting fructosamine levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline fructosamine value is the last non-missing value before the start of treatment. Change from Baseline in fructosamine was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16</measure>
    <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
    <description>Fasting C-peptide levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline C-peptide value is the last non-missing value before the start of treatment. Change from Baseline in C-peptide was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16</measure>
    <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
    <description>Fasting glucagon levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline glucagon value is the last non-missing value before the start of treatment. Change from Baseline in glucagon was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16</measure>
    <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
    <description>Fasting insulin levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline insulin value is the last non-missing value before the start of treatment. Change from Baseline in insulin was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16</measure>
    <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
    <description>Serum lipid components, including triglycerides (TG), free fatty acids (FFA), total cholesterol (CL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), were measured at Baseline and Weeks 5, 8, 12, and 16. The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The FLIE questionnaire is used to record the participant's feelings/opinions concerning the effects of nausea/vomiting on their quality of life during the past five days. Participants completed the questionnaire by responding to 18 questions. The first set of 9 questions refer to nausea, and the second set of 9 questions refer to vomiting. Each question is scored on a seven-point visual analog scale (1 to 7). On this scale, a score of 1 corresponds to 0 millimeters (mm), and a score of 7 correspond to 100 mm. Anything in between is marked at the appropriate point on the scale and is measured in mm. Data are reported in mm in this table. In FLIE questions (FLIEQ) 1, 2, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, and 17, a score of 1 indicates no effect on the quality of life, and a score of 7 indicates a great effect on the quality of life. In FLIEQ 3, 6, 11, 15, and 18, a score of 1 indicates a great effect on the quality of life, and a score of 7 indicates no effect on the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The HCFQ questionnaire is used to record how often participants have felt hungry or craved food, and how full participants felt after finishing meals, on average, in the past week. Participants answered the following seven questions with the response that best described their feelings of hunger, craving, and fullness: Q1, &quot;In the past week I was hungry&quot;; Q2, &quot;In the past week I thought about food&quot;; Q3, &quot;In the past week I wanted to eat&quot;; Q4, &quot;In the past week I ate more than I should have&quot;; Q5, &quot;In the past week, I craved specific food&quot;; Q6, &quot;In the past week when finished meals I felt full&quot;; Q7, &quot;In the past week when finished meals I felt satisfied.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clearance of Albiglutide</measure>
    <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
    <description>Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose pharmacokinetic (PK) sampling was performed within 6 days of drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Volume of Distribution of Albiglutide</measure>
    <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
    <description>Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absorption Rate of Albiglutide</measure>
    <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
    <description>Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG</measure>
    <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
    <description>EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model.</description>
  </secondary_outcome>
  <enrollment type="Actual">361</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albiglutide (GSK716155) or exenatide</intervention_name>
    <description>Albiglutide weekly subcutaneous injection or exenatide twice daily injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has type 2 diabetes mellitus as defined by the criteria of the American Diabetes
             Association and recognized by World Health Organization Expert Committee on the
             Diagnosis and Classification of Diabetes Mellitus [American Diabetes Association,
             2004a] at least three months preceding screening

          -  Has concurrent type 2 diabetes mellitus therapy: Must be diet and exercise treated;
             must not have taken antidiabetic medication for at least three months prior to
             prescreening or Monotherapy with metformin, with a history of a stable dose for at
             least three months before prescreening (not taking more than one oral antidiabetic
             agent)

          -  Has HbA1c level at screening ≥7 and ≤10%

          -  Is male or female 18 to 75 years of age, inclusive, at screening

          -  Has body mass index ≥20 and ≤40 kg/m²

          -  If subject is a smoker, must be able to abstain while in clinic at each visit

          -  If female, is eligible to enter and participate throughout the study, including the
             follow-up period: 1) If of nonchildbearing potential (i.e. physiologically incapable
             of becoming pregnant {tubal ligation}, including any female who is postmenopausal [&gt;1
             year without menstrual period]); or, 2) If of childbearing potential, has negative
             pregnancy tests at screening (serum) and at baseline (urine) and: 3) Has a male
             partner who is sterile prior to the female subject's entry into the study and is the
             sole sexual partner for that female subject, or 4) Uses double-barrier methods of
             contraception; condoms (with spermicide) and intrauterine devices are acceptable, or
             5) Uses hormonal contraceptives (oral, depots, patches, etc) with double-barrier
             methods of contraception as outlined above, or, 6) Abstains from sexual intercourse,
             or 7) Is with a same-sex partner and does not participate in bisexual activities where
             there is any risk of pregnancy

          -  Signs and dates informed consent before any study-related procedures are performed

        Exclusion Criteria:

          -  Has metabolic disease including but not limited to: 1) Diagnosis of type 1 diabetes
             mellitus, 2) Uncorrected thyroid dysfunction (NOTE: subjects with hypothyroidism on a
             stable dose of thyroid replacement therapy for at least three months prior to
             screening, and who have a screening thyroid-stimulating hormone within the limits of
             normal may participate)

          -  Has qualitative changes in lifestyle that, in the opinion of the investigator, would
             affect the subject's weight or disease status

          -  Had previous use of insulin within one month prior to screening, or more than seven
             total days of insulin treatment within three months prior to screening

          -  Has clinically significant cardiovascular and/or cerebrovascular disease including,
             but not limited to: 1) Previous history of stroke or transient ischemic attack, 2)
             Active, unstable coronary heart disease within the past six months, 3) Documented
             myocardial infarction within a year prior to screening 4) Any cardiac surgery
             including percutaneous transluminal coronary angioplasty or coronary artery bypass
             graft surgery within a year prior to screening 5) Unstable angina 6) Clinically
             significant arrhythmia or valvular heart disease within the past year 7) Congestive
             heart failure with New York Heart Association Class II to Class IV symptoms. Class I
             is acceptable. 8) Untreated hypertension, with systolic pressure greater than 160mm Hg
             and/or diastolic pressure greater than 95mm Hg. 9) ECG exclusion criteria: Heart rate
             is &lt;40 and &gt;110 beats per minute, PR Interval is &lt;120 and &gt;210msec, QRS duration is
             &lt;70 and &gt;120msec, QTc interval (Bazett) is &gt;450msec or &gt;480msec with bundle branch
             block

          -  Has fasting serum triglycerides ≥800mg/dL or 9mmol/L at screening (Visit 2). Subjects
             receiving lipid-lowering therapy must have been on the same dose of therapy for the
             past three months. Fasting is defined as no food/drink for at least eight hours prior
             to sampling

          -  If female, is currently lactating, pregnant, or actively trying to become pregnant

          -  Has significant renal disease as manifested by one or more of the following: 1)
             Creatinine clearance &lt;60mL/min. (estimated from serum creatinine and demographic data
             using the modification of diet in renal disease calculation; refer to the SPM/ISFM),
             2) Urine albumin excretion ≥500 µg/mL on a urine spot check, 3) Known loss of a kidney
             either by surgical ablation, injury, or disease

          -  Has history of significant comorbid diseases active within the last six months (e.g.,
             gastrointestinal disease)

          -  Has history of pancreatitis within five years prior to randomization

          -  Has a documented history of chronic or advanced hepatobiliary disease including a
             history of, or positive laboratory results for, hepatitis at screening (Visit 2),
             and/or clinically significant hepatic enzyme elevation including: 1) Any two of the
             following enzymes greater than 1.5 times the upper limit of normal (ULN) value: -
             alanine aminotransferase (ALT), - aspartate aminotransferase (AST), - alkaline
             phosphatase (ALP), 2) Any one of the above enzymes two times greater than the ULN
             value AND total or direct bilirubin &gt;1.5 times the ULN

          -  Has a history of alcohol or substance abuse within the past year, as determined by the
             investigator or a positive urine drug screen at screening (Visit 2) or during
             treatment: 1) Unwilling to refrain from the use of excessive alcohol or illicit drugs
             and adhere to other protocol-stated restrictions while participating in the study, 2)
             History of alcohol abuse defined as an average weekly intake of greater than 21 units
             or an average daily intake of greater than three units (males) or defined as an
             average weekly intake of greater than 14 units or an average daily intake of greater
             than two units (females). One unit is equivalent to a half-pint of beer or one measure
             of spirits or one glass of wine, 2) The investigator should exercise their medical
             judgment to determine if a urine drug screen is indicated

          -  Is currently taking prohibited concomitant medications listed in Section 6.6.2

          -  Has clinically significant anemia (i.e., hemoglobin &lt;12.0g/dL or &lt;120.0g/L for males
             and &lt;11.0g/dL or &lt;110.0g/L for females) or any other abnormal hematological profile
             that is considered by the investigator to be clinically significant

          -  Has known allergy to any formulation excipients, or history of drug or other allergy,
             which, in the opinion of the responsible study physician, contradicts participation

          -  Received treatment with an investigational drug or participated in any other clinical
             trial during the previous 30 days

          -  Has prior use of investigational agents with long half-lives of greater than seven
             days within the three months prior to screening

          -  Has any prior use of a GLP-1 analog, including GSK716155

          -  In the opinion of the investigator, has a risk of noncompliance with study procedures,
             or cannot read, understand, or complete study-related materials, particularly the
             informed consent

          -  Has any concurrent condition or any clinically significant abnormality identified on
             the screening physical examination, laboratory tests, ECG, including pulmonary,
             neurological, or inflammatory diseases, which, in the opinion of the investigator, may
             affect the interpretation of efficacy and safety data, or which otherwise,
             contraindicates participation in a clinical trial with a new chemical entity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bull Shoals</city>
        <state>Arizona</state>
        <zip>72619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arizona</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211-3733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <zip>72143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Forest</city>
        <state>California</state>
        <zip>92630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reedley</city>
        <state>California</state>
        <zip>93654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Van Buys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marianna</city>
        <state>Florida</state>
        <zip>32446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <zip>31069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Grange</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Watseka</city>
        <state>Illinois</state>
        <zip>60970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lacombe</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01831-2451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caro</city>
        <state>Michigan</state>
        <zip>48723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rolling Fork</city>
        <state>Mississippi</state>
        <zip>39159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chadbourn</city>
        <state>North Carolina</state>
        <zip>28431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mint Hill</city>
        <state>North Carolina</state>
        <zip>28227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morrisville</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milan</city>
        <state>Tennessee</state>
        <zip>38358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleburne</city>
        <state>Texas</state>
        <zip>76033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Euless</city>
        <state>Texas</state>
        <zip>76040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>LaPorte</city>
        <state>Texas</state>
        <zip>77571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <zip>78577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chester</city>
        <state>Virginia</state>
        <zip>23836</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Washington</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concepcion</city>
        <state>Región Del Biobio</state>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buin</city>
        <state>Región Metro De Santiago</state>
        <zip>9500645</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500010</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8320268</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009 Oct;32(10):1880-6. doi: 10.2337/dc09-0366. Epub 2009 Jul 10.</citation>
    <PMID>19592625</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <results_first_submitted>May 1, 2014</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2014</results_first_posted>
  <disposition_first_submitted>July 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLP-1,</keyword>
  <keyword>Type 2 Diabetes,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>GSK716155,</keyword>
  <keyword>metformin,</keyword>
  <keyword>exenatide</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>rGLP-1 protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP110125</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 361 participants were randomized into the study; however, only 356 of these participants received at least one dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P2">
          <title>Exenatide BID</title>
          <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
        </group>
        <group group_id="P3">
          <title>Albiglutide 4 mg Weekly</title>
          <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P4">
          <title>Albiglutide 15 mg Weekly</title>
          <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P5">
          <title>Albiglutide 30 mg Weekly</title>
          <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P6">
          <title>Albiglutide 15 mg Bi-weekly</title>
          <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P7">
          <title>Albiglutide 30 mg Bi-weekly</title>
          <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P8">
          <title>Albiglutide 50 mg Bi-weekly</title>
          <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P9">
          <title>Albiglutide 50 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="P10">
          <title>Albiglutide 100 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="33"/>
                <participants group_id="P8" count="35"/>
                <participants group_id="P9" count="35"/>
                <participants group_id="P10" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="51">These participants received at least one dose of study drug.</participants>
                <participants group_id="P2" count="35">These participants received at least one dose of study drug.</participants>
                <participants group_id="P3" count="35">These participants received at least one dose of study drug.</participants>
                <participants group_id="P4" count="35">These participants received at least one dose of study drug.</participants>
                <participants group_id="P5" count="31">These participants received at least one dose of study drug.</participants>
                <participants group_id="P6" count="33">These participants received at least one dose of study drug.</participants>
                <participants group_id="P7" count="32">These participants received at least one dose of study drug.</participants>
                <participants group_id="P8" count="35">These participants received at least one dose of study drug.</participants>
                <participants group_id="P9" count="35">These participants received at least one dose of study drug.</participants>
                <participants group_id="P10" count="34">These participants received at least one dose of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Eligibility Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Prescribed Antidiabetic Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Different Monotherapy Diabetic Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Wrong Monotherapy Administered</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family Emergency; Had to Go to England</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved Out of State</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B2">
          <title>Exenatide BID</title>
          <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
        </group>
        <group group_id="B3">
          <title>Albiglutide 4 mg Weekly</title>
          <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B4">
          <title>Albiglutide 15 mg Weekly</title>
          <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B5">
          <title>Albiglutide 30 mg Weekly</title>
          <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B6">
          <title>Albiglutide 15 mg Bi-weekly</title>
          <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B7">
          <title>Albiglutide 30 mg Bi-weekly</title>
          <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B8">
          <title>Albiglutide 50 mg Bi-weekly</title>
          <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B9">
          <title>Albiglutide 50 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B10">
          <title>Albiglutide 100 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="33"/>
            <count group_id="B7" value="32"/>
            <count group_id="B8" value="35"/>
            <count group_id="B9" value="35"/>
            <count group_id="B10" value="34"/>
            <count group_id="B11" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline data are reported for participants in the Safety Population, comprised of all randomly assigned participants who received at least one dose of study drug.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="10.62"/>
                    <measurement group_id="B2" value="53.7" spread="9.38"/>
                    <measurement group_id="B3" value="50.4" spread="10.25"/>
                    <measurement group_id="B4" value="55.5" spread="10.48"/>
                    <measurement group_id="B5" value="54.2" spread="9.66"/>
                    <measurement group_id="B6" value="52.5" spread="9.55"/>
                    <measurement group_id="B7" value="55.5" spread="9.87"/>
                    <measurement group_id="B8" value="51.1" spread="10.25"/>
                    <measurement group_id="B9" value="54.1" spread="11.30"/>
                    <measurement group_id="B10" value="54.4" spread="9.89"/>
                    <measurement group_id="B11" value="53.5" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline data are reported for participants in the Safety Population, comprised of all randomly assigned participants who received at least one dose of study drug.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Baseline data are reported for participants in the Safety Population, comprised of all randomly assigned participants who received at least one dose of study drug.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White- Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic, Puerto Rican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mulatto</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16</title>
        <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomly assigned participants with at least one post-Baseline assessment of the primary endpoint. Participants from the exenatide arm were not included in the analysis. Only those participants with a value at Baseline and at the specified visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16</title>
          <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>Intent-to-Treat (ITT) Population: all randomly assigned participants with at least one post-Baseline assessment of the primary endpoint. Participants from the exenatide arm were not included in the analysis. Only those participants with a value at Baseline and at the specified visit were analyzed.</population>
          <units>Percentage of HbA1c in the blood</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.136"/>
                    <measurement group_id="O3" value="-0.25" spread="0.159"/>
                    <measurement group_id="O4" value="-0.71" spread="0.160"/>
                    <measurement group_id="O5" value="-1.08" spread="0.175"/>
                    <measurement group_id="O6" value="-0.68" spread="0.167"/>
                    <measurement group_id="O7" value="-1.01" spread="0.162"/>
                    <measurement group_id="O8" value="-1.03" spread="0.159"/>
                    <measurement group_id="O9" value="-0.80" spread="0.157"/>
                    <measurement group_id="O10" value="-1.06" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2968</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1860</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2766</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0786</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
        <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
          <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Percentage of HbA1c in the blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=47,34,33,34,28,29,31,34,34,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.538"/>
                    <measurement group_id="O2" value="-0.23" spread="0.485"/>
                    <measurement group_id="O3" value="-0.12" spread="0.658"/>
                    <measurement group_id="O4" value="-0.33" spread="0.442"/>
                    <measurement group_id="O5" value="-0.56" spread="0.401"/>
                    <measurement group_id="O6" value="-0.35" spread="0.470"/>
                    <measurement group_id="O7" value="-0.34" spread="0.678"/>
                    <measurement group_id="O8" value="-0.45" spread="0.547"/>
                    <measurement group_id="O9" value="-0.41" spread="0.429"/>
                    <measurement group_id="O10" value="-0.42" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=49,34,34,34,29,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.570"/>
                    <measurement group_id="O2" value="-0.32" spread="0.495"/>
                    <measurement group_id="O3" value="-0.16" spread="0.758"/>
                    <measurement group_id="O4" value="-0.39" spread="0.516"/>
                    <measurement group_id="O5" value="-0.62" spread="0.439"/>
                    <measurement group_id="O6" value="-0.42" spread="0.625"/>
                    <measurement group_id="O7" value="-0.51" spread="0.756"/>
                    <measurement group_id="O8" value="-0.58" spread="0.554"/>
                    <measurement group_id="O9" value="-0.47" spread="0.608"/>
                    <measurement group_id="O10" value="-0.65" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.749"/>
                    <measurement group_id="O2" value="-0.36" spread="0.554"/>
                    <measurement group_id="O3" value="-0.19" spread="0.855"/>
                    <measurement group_id="O4" value="-0.44" spread="0.619"/>
                    <measurement group_id="O5" value="-0.79" spread="0.474"/>
                    <measurement group_id="O6" value="-0.52" spread="0.648"/>
                    <measurement group_id="O7" value="0.64" spread="0.890"/>
                    <measurement group_id="O8" value="-0.68" spread="0.831"/>
                    <measurement group_id="O9" value="-0.45" spread="0.801"/>
                    <measurement group_id="O10" value="-0.63" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.793"/>
                    <measurement group_id="O2" value="-0.45" spread="0.588"/>
                    <measurement group_id="O3" value="-0.24" spread="0.897"/>
                    <measurement group_id="O4" value="-0.50" spread="0.659"/>
                    <measurement group_id="O5" value="-0.77" spread="0.494"/>
                    <measurement group_id="O6" value="-0.54" spread="0.679"/>
                    <measurement group_id="O7" value="-0.67" spread="0.928"/>
                    <measurement group_id="O8" value="-0.71" spread="0.834"/>
                    <measurement group_id="O9" value="-0.41" spread="0.823"/>
                    <measurement group_id="O10" value="-0.68" spread="0.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.842"/>
                    <measurement group_id="O2" value="-0.51" spread="0.633"/>
                    <measurement group_id="O3" value="-0.19" spread="0.947"/>
                    <measurement group_id="O4" value="-0.55" spread="0.713"/>
                    <measurement group_id="O5" value="-0.85" spread="0.559"/>
                    <measurement group_id="O6" value="-0.56" spread="0.767"/>
                    <measurement group_id="O7" value="-0.71" spread="0.929"/>
                    <measurement group_id="O8" value="-0.77" spread="0.842"/>
                    <measurement group_id="O9" value="-0.54" spread="0.836"/>
                    <measurement group_id="O10" value="-0.82" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.892"/>
                    <measurement group_id="O2" value="-0.56" spread="0.868"/>
                    <measurement group_id="O3" value="-0.18" spread="1.025"/>
                    <measurement group_id="O4" value="-0.58" spread="0.813"/>
                    <measurement group_id="O5" value="-0.96" spread="0.649"/>
                    <measurement group_id="O6" value="-0.59" spread="0.913"/>
                    <measurement group_id="O7" value="-0.71" spread="1.003"/>
                    <measurement group_id="O8" value="-0.79" spread="0.852"/>
                    <measurement group_id="O9" value="-0.51" spread="0.942"/>
                    <measurement group_id="O10" value="-0.84" spread="0.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.948"/>
                    <measurement group_id="O2" value="-0.53" spread="0.865"/>
                    <measurement group_id="O3" value="-0.19" spread="0.989"/>
                    <measurement group_id="O4" value="-0.49" spread="0.819"/>
                    <measurement group_id="O5" value="-0.86" spread="0.607"/>
                    <measurement group_id="O6" value="-0.61" spread="0.929"/>
                    <measurement group_id="O7" value="-0.79" spread="1.044"/>
                    <measurement group_id="O8" value="-0.80" spread="1.041"/>
                    <measurement group_id="O9" value="-0.58" spread="1.016"/>
                    <measurement group_id="O10" value="-0.88" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.006"/>
                    <measurement group_id="O2" value="-0.54" spread="0.906"/>
                    <measurement group_id="O3" value="-0.11" spread="1.156"/>
                    <measurement group_id="O4" value="-0.49" spread="0.740"/>
                    <measurement group_id="O5" value="-0.87" spread="0.652"/>
                    <measurement group_id="O6" value="-0.56" spread="0.971"/>
                    <measurement group_id="O7" value="-0.79" spread="0.978"/>
                    <measurement group_id="O8" value="-0.79" spread="1.036"/>
                    <measurement group_id="O9" value="-0.55" spread="1.012"/>
                    <measurement group_id="O10" value="-0.87" spread="0.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Target Values for HbA1c &lt;6.5% and &gt;=6.5% to &lt;7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
        <description>The number of participants who achieved target values for HbA1c (i.e., HbA1c &lt;6.5% and &gt;=6.5% to &lt;7%) were assessed. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Weeks (W) 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Target Values for HbA1c &lt;6.5% and &gt;=6.5% to &lt;7% at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
          <description>The number of participants who achieved target values for HbA1c (i.e., HbA1c &lt;6.5% and &gt;=6.5% to &lt;7%) were assessed. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>W4: &lt;6.5%, n=47,34,33,34,28,29,31,34,34,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4: &gt;=6.5% to &lt;7%, n=47,34,33,34,28,29,31,34,34,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W5: &lt;6.5%, n=49,34,34,34,29,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W5: &gt;=6.5% to &lt;7%, n=49,34,34,34,29,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W7: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W7: &gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8: &gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W9: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W9: &gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W12: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W12:&gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W15: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W15:&gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: &lt;6.5%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16:&gt;=6.5% to &lt;7%, n=50,34,34,34,29,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at Week 16</title>
        <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in waist circumference was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at Week 16</title>
          <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in waist circumference was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="3.847"/>
                    <measurement group_id="O2" value="-3.53" spread="8.532"/>
                    <measurement group_id="O3" value="-1.50" spread="3.902"/>
                    <measurement group_id="O4" value="-3.16" spread="6.901"/>
                    <measurement group_id="O5" value="-1.14" spread="3.856"/>
                    <measurement group_id="O6" value="-1.83" spread="3.392"/>
                    <measurement group_id="O7" value="-0.47" spread="3.589"/>
                    <measurement group_id="O8" value="-2.00" spread="5.454"/>
                    <measurement group_id="O9" value="-0.88" spread="5.146"/>
                    <measurement group_id="O10" value="-0.77" spread="4.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 16</title>
        <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 16</title>
          <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
          <units>Kilograms (Kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="2.883"/>
                    <measurement group_id="O2" value="-2.41" spread="3.527"/>
                    <measurement group_id="O3" value="-0.91" spread="1.733"/>
                    <measurement group_id="O4" value="-0.90" spread="2.901"/>
                    <measurement group_id="O5" value="-1.43" spread="2.371"/>
                    <measurement group_id="O6" value="-1.76" spread="2.828"/>
                    <measurement group_id="O7" value="-1.59" spread="2.455"/>
                    <measurement group_id="O8" value="-1.14" spread="2.872"/>
                    <measurement group_id="O9" value="-1.08" spread="3.177"/>
                    <measurement group_id="O10" value="-1.65" spread="3.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at Week 16</title>
        <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. Percent change from Baseline was calculated as the ([value at Week 16 minus the Baseline value] divided by the Baseline value) multiplied by 100. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at Week 16</title>
          <description>The Baseline value is the last non-missing value before the start of treatment. Change from Baseline in body weight was calculated as the value at Week 16 minus the value at Baseline. Percent change from Baseline was calculated as the ([value at Week 16 minus the Baseline value] divided by the Baseline value) multiplied by 100. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only participants with a value at Baseline and at Week 16 were analyzed.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="3.403"/>
                    <measurement group_id="O2" value="-2.53" spread="4.307"/>
                    <measurement group_id="O3" value="-0.94" spread="1.838"/>
                    <measurement group_id="O4" value="-1.04" spread="3.261"/>
                    <measurement group_id="O5" value="-1.59" spread="2.663"/>
                    <measurement group_id="O6" value="-1.97" spread="2.908"/>
                    <measurement group_id="O7" value="-1.69" spread="2.773"/>
                    <measurement group_id="O8" value="-1.32" spread="3.160"/>
                    <measurement group_id="O9" value="-1.37" spread="3.571"/>
                    <measurement group_id="O10" value="-1.89" spread="3.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
        <description>The FPG test measures blood sugar levels after the participant has not eaten (fasted) for at least eight hours prior to the sampling. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FPG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 4, 5, 7, 8, 9, 12, 15, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 5, 7, 8, 9, 12, 15, and 16</title>
          <description>The FPG test measures blood sugar levels after the participant has not eaten (fasted) for at least eight hours prior to the sampling. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FPG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=47,33,32,32,29,28,32,32,34,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.565"/>
                    <measurement group_id="O2" value="-1.11" spread="1.953"/>
                    <measurement group_id="O3" value="-0.99" spread="3.037"/>
                    <measurement group_id="O4" value="-0.58" spread="1.693"/>
                    <measurement group_id="O5" value="-1.39" spread="1.968"/>
                    <measurement group_id="O6" value="-1.06" spread="2.110"/>
                    <measurement group_id="O7" value="-0.97" spread="1.629"/>
                    <measurement group_id="O8" value="-1.35" spread="2.533"/>
                    <measurement group_id="O9" value="-0.14" spread="3.192"/>
                    <measurement group_id="O10" value="-0.61" spread="2.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=47,33,32,32,29,28,32,32,34,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.774"/>
                    <measurement group_id="O2" value="-1.06" spread="2.377"/>
                    <measurement group_id="O3" value="-1.02" spread="2.964"/>
                    <measurement group_id="O4" value="-1.05" spread="1.705"/>
                    <measurement group_id="O5" value="-1.53" spread="1.898"/>
                    <measurement group_id="O6" value="-1.41" spread="2.363"/>
                    <measurement group_id="O7" value="-1.72" spread="1.933"/>
                    <measurement group_id="O8" value="-2.17" spread="2.453"/>
                    <measurement group_id="O9" value="-1.55" spread="3.032"/>
                    <measurement group_id="O10" value="-2.12" spread="1.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="2.924"/>
                    <measurement group_id="O2" value="-1.25" spread="2.204"/>
                    <measurement group_id="O3" value="-0.80" spread="2.942"/>
                    <measurement group_id="O4" value="-0.13" spread="2.261"/>
                    <measurement group_id="O5" value="-1.54" spread="1.723"/>
                    <measurement group_id="O6" value="-1.16" spread="2.651"/>
                    <measurement group_id="O7" value="-1.51" spread="2.065"/>
                    <measurement group_id="O8" value="-1.87" spread="2.801"/>
                    <measurement group_id="O9" value="-0.41" spread="2.844"/>
                    <measurement group_id="O10" value="-1.07" spread="2.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="2.689"/>
                    <measurement group_id="O2" value="-1.43" spread="2.258"/>
                    <measurement group_id="O3" value="-1.22" spread="2.958"/>
                    <measurement group_id="O4" value="-0.80" spread="1.856"/>
                    <measurement group_id="O5" value="-1.60" spread="1.925"/>
                    <measurement group_id="O6" value="-1.29" spread="2.520"/>
                    <measurement group_id="O7" value="-1.27" spread="2.092"/>
                    <measurement group_id="O8" value="-1.29" spread="2.655"/>
                    <measurement group_id="O9" value="-0.66" spread="2.202"/>
                    <measurement group_id="O10" value="-1.29" spread="2.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="3.185"/>
                    <measurement group_id="O2" value="-1.54" spread="2.044"/>
                    <measurement group_id="O3" value="-1.13" spread="2.915"/>
                    <measurement group_id="O4" value="-0.71" spread="1.674"/>
                    <measurement group_id="O5" value="-1.49" spread="2.122"/>
                    <measurement group_id="O6" value="-1.29" spread="2.617"/>
                    <measurement group_id="O7" value="-1.64" spread="2.505"/>
                    <measurement group_id="O8" value="-1.68" spread="3.012"/>
                    <measurement group_id="O9" value="-1.48" spread="2.887"/>
                    <measurement group_id="O10" value="-2.25" spread="2.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.833"/>
                    <measurement group_id="O2" value="-1.32" spread="2.518"/>
                    <measurement group_id="O3" value="-1.04" spread="2.863"/>
                    <measurement group_id="O4" value="-0.70" spread="2.413"/>
                    <measurement group_id="O5" value="-1.85" spread="1.722"/>
                    <measurement group_id="O6" value="-1.11" spread="2.492"/>
                    <measurement group_id="O7" value="-1.57" spread="2.196"/>
                    <measurement group_id="O8" value="-1.49" spread="2.908"/>
                    <measurement group_id="O9" value="-0.49" spread="3.103"/>
                    <measurement group_id="O10" value="-1.50" spread="3.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="2.733"/>
                    <measurement group_id="O2" value="-1.27" spread="2.343"/>
                    <measurement group_id="O3" value="-0.67" spread="2.984"/>
                    <measurement group_id="O4" value="-0.70" spread="1.755"/>
                    <measurement group_id="O5" value="-1.54" spread="1.680"/>
                    <measurement group_id="O6" value="-1.45" spread="2.320"/>
                    <measurement group_id="O7" value="-1.71" spread="2.133"/>
                    <measurement group_id="O8" value="-1.66" spread="3.662"/>
                    <measurement group_id="O9" value="-0.79" spread="2.757"/>
                    <measurement group_id="O10" value="-1.27" spread="3.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=47,33,32,32,29,28,32,32,34,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="2.895"/>
                    <measurement group_id="O2" value="-0.80" spread="2.482"/>
                    <measurement group_id="O3" value="-0.47" spread="3.118"/>
                    <measurement group_id="O4" value="-0.72" spread="1.683"/>
                    <measurement group_id="O5" value="-1.44" spread="2.027"/>
                    <measurement group_id="O6" value="-1.28" spread="2.427"/>
                    <measurement group_id="O7" value="-1.58" spread="2.059"/>
                    <measurement group_id="O8" value="-1.32" spread="3.523"/>
                    <measurement group_id="O9" value="-0.72" spread="2.765"/>
                    <measurement group_id="O10" value="-1.22" spread="3.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16</title>
        <description>Fasting fructosamine levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline fructosamine value is the last non-missing value before the start of treatment. Change from Baseline in fructosamine was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Fructosamine at Weeks 5, 8, 12, and 16</title>
          <description>Fasting fructosamine levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline fructosamine value is the last non-missing value before the start of treatment. Change from Baseline in fructosamine was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Micromoles per liter (µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5, n=48,34,32,33,28,29,32,34,35,29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="38.68"/>
                    <measurement group_id="O2" value="-24.7" spread="38.65"/>
                    <measurement group_id="O3" value="-11.9" spread="50.55"/>
                    <measurement group_id="O4" value="-23.8" spread="20.74"/>
                    <measurement group_id="O5" value="-30.7" spread="31.28"/>
                    <measurement group_id="O6" value="-21.3" spread="36.67"/>
                    <measurement group_id="O7" value="-34.4" spread="41.71"/>
                    <measurement group_id="O8" value="-30.1" spread="41.75"/>
                    <measurement group_id="O9" value="-29.2" spread="46.57"/>
                    <measurement group_id="O10" value="-32.5" spread="32.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=50,34,33,34,28,29,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="41.37"/>
                    <measurement group_id="O2" value="-30.6" spread="32.47"/>
                    <measurement group_id="O3" value="-13.1" spread="50.64"/>
                    <measurement group_id="O4" value="-25.7" spread="31.34"/>
                    <measurement group_id="O5" value="-35.5" spread="26.97"/>
                    <measurement group_id="O6" value="-28.9" spread="42.46"/>
                    <measurement group_id="O7" value="-40.9" spread="43.73"/>
                    <measurement group_id="O8" value="-32.7" spread="42.44"/>
                    <measurement group_id="O9" value="-24.9" spread="40.03"/>
                    <measurement group_id="O10" value="-29.5" spread="49.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=50,34,33,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="41.61"/>
                    <measurement group_id="O2" value="-30.1" spread="35.78"/>
                    <measurement group_id="O3" value="-12.5" spread="55.41"/>
                    <measurement group_id="O4" value="-26.7" spread="30.61"/>
                    <measurement group_id="O5" value="-31.8" spread="35.07"/>
                    <measurement group_id="O6" value="-25.2" spread="46.21"/>
                    <measurement group_id="O7" value="-40.2" spread="43.37"/>
                    <measurement group_id="O8" value="-32.7" spread="48.01"/>
                    <measurement group_id="O9" value="-26.4" spread="46.85"/>
                    <measurement group_id="O10" value="-31.1" spread="52.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=50,34,33,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="46.33"/>
                    <measurement group_id="O2" value="-24.6" spread="41.88"/>
                    <measurement group_id="O3" value="-7.8" spread="56.38"/>
                    <measurement group_id="O4" value="-18.2" spread="28.01"/>
                    <measurement group_id="O5" value="-30.8" spread="31.05"/>
                    <measurement group_id="O6" value="-23.0" spread="49.58"/>
                    <measurement group_id="O7" value="-38.1" spread="43.17"/>
                    <measurement group_id="O8" value="-29.4" spread="56.23"/>
                    <measurement group_id="O9" value="-26.5" spread="40.27"/>
                    <measurement group_id="O10" value="-24.9" spread="49.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16</title>
        <description>Fasting C-peptide levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline C-peptide value is the last non-missing value before the start of treatment. Change from Baseline in C-peptide was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting C-peptide at Weeks 5, 8, 12, and 16</title>
          <description>Fasting C-peptide levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline C-peptide value is the last non-missing value before the start of treatment. Change from Baseline in C-peptide was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Nanomoles per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5, n=48,33,32,33,27,28,32,33,35,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.4464"/>
                    <measurement group_id="O2" value="0.274" spread="0.7431"/>
                    <measurement group_id="O3" value="-0.020" spread="0.3374"/>
                    <measurement group_id="O4" value="-0.034" spread="0.6149"/>
                    <measurement group_id="O5" value="0.089" spread="0.3459"/>
                    <measurement group_id="O6" value="0.015" spread="0.3782"/>
                    <measurement group_id="O7" value="-0.128" spread="0.6990"/>
                    <measurement group_id="O8" value="0.004" spread="0.4130"/>
                    <measurement group_id="O9" value="0.072" spread="0.4130"/>
                    <measurement group_id="O10" value="0.230" spread="0.3595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=50,34,33,34,28,29,32,33,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.4044"/>
                    <measurement group_id="O2" value="0.104" spread="0.4643"/>
                    <measurement group_id="O3" value="-0.073" spread="0.2813"/>
                    <measurement group_id="O4" value="-0.026" spread="0.6237"/>
                    <measurement group_id="O5" value="0.095" spread="0.5520"/>
                    <measurement group_id="O6" value="-0.038" spread="0.3931"/>
                    <measurement group_id="O7" value="-0.015" spread="0.7842"/>
                    <measurement group_id="O8" value="-0.062" spread="0.3735"/>
                    <measurement group_id="O9" value="0.031" spread="0.4738"/>
                    <measurement group_id="O10" value="0.007" spread="0.3363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=50,34,33,34,28,29,32,33,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.092" spread="0.4264"/>
                    <measurement group_id="O2" value="0.174" spread="0.5445"/>
                    <measurement group_id="O3" value="-0.044" spread="0.3426"/>
                    <measurement group_id="O4" value="-0.046" spread="0.5904"/>
                    <measurement group_id="O5" value="0.023" spread="0.3698"/>
                    <measurement group_id="O6" value="-0.098" spread="0.3773"/>
                    <measurement group_id="O7" value="-0.153" spread="0.6463"/>
                    <measurement group_id="O8" value="-0.076" spread="0.4458"/>
                    <measurement group_id="O9" value="0.155" spread="0.5257"/>
                    <measurement group_id="O10" value="0.062" spread="0.6038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=50,34,33,34,28,29,32,33,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.3149"/>
                    <measurement group_id="O2" value="0.216" spread="0.6786"/>
                    <measurement group_id="O3" value="-0.051" spread="0.3877"/>
                    <measurement group_id="O4" value="-0.075" spread="0.6046"/>
                    <measurement group_id="O5" value="0.171" spread="0.4400"/>
                    <measurement group_id="O6" value="-0.059" spread="0.4010"/>
                    <measurement group_id="O7" value="-0.137" spread="0.6540"/>
                    <measurement group_id="O8" value="-0.066" spread="0.4025"/>
                    <measurement group_id="O9" value="0.076" spread="0.5365"/>
                    <measurement group_id="O10" value="-0.005" spread="0.4312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16</title>
        <description>Fasting glucagon levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline glucagon value is the last non-missing value before the start of treatment. Change from Baseline in glucagon was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucagon at Weeks 5, 8, 12, and 16</title>
          <description>Fasting glucagon levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline glucagon value is the last non-missing value before the start of treatment. Change from Baseline in glucagon was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Nanograms per liter (ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5, n=48,33,33,33,27,28,32,34,35,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="43.63"/>
                    <measurement group_id="O2" value="-3.9" spread="39.26"/>
                    <measurement group_id="O3" value="-3.2" spread="27.16"/>
                    <measurement group_id="O4" value="-13.9" spread="29.05"/>
                    <measurement group_id="O5" value="-3.6" spread="21.95"/>
                    <measurement group_id="O6" value="-6.0" spread="26.83"/>
                    <measurement group_id="O7" value="-7.6" spread="20.72"/>
                    <measurement group_id="O8" value="-11.6" spread="29.48"/>
                    <measurement group_id="O9" value="-9.3" spread="23.21"/>
                    <measurement group_id="O10" value="1.9" spread="30.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=50,34,34,34,28,29,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="49.05"/>
                    <measurement group_id="O2" value="-14.8" spread="38.34"/>
                    <measurement group_id="O3" value="-5.6" spread="22.91"/>
                    <measurement group_id="O4" value="-15.6" spread="32.75"/>
                    <measurement group_id="O5" value="-2.4" spread="17.78"/>
                    <measurement group_id="O6" value="-12.4" spread="32.17"/>
                    <measurement group_id="O7" value="-3.1" spread="22.64"/>
                    <measurement group_id="O8" value="-10.7" spread="34.48"/>
                    <measurement group_id="O9" value="-0.3" spread="41.71"/>
                    <measurement group_id="O10" value="0.5" spread="27.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=50,34,34,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="49.48"/>
                    <measurement group_id="O2" value="-5.5" spread="32.41"/>
                    <measurement group_id="O3" value="-8.6" spread="31.51"/>
                    <measurement group_id="O4" value="-20.1" spread="36.53"/>
                    <measurement group_id="O5" value="-4.5" spread="21.60"/>
                    <measurement group_id="O6" value="-11.1" spread="39.08"/>
                    <measurement group_id="O7" value="0.2" spread="24.55"/>
                    <measurement group_id="O8" value="-3.3" spread="35.85"/>
                    <measurement group_id="O9" value="-3.7" spread="38.02"/>
                    <measurement group_id="O10" value="-2.1" spread="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=50,34,34,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="45.73"/>
                    <measurement group_id="O2" value="-4.5" spread="41.10"/>
                    <measurement group_id="O3" value="-3.9" spread="26.72"/>
                    <measurement group_id="O4" value="-20.5" spread="36.06"/>
                    <measurement group_id="O5" value="-2.6" spread="22.70"/>
                    <measurement group_id="O6" value="-7.1" spread="32.75"/>
                    <measurement group_id="O7" value="-5.0" spread="17.95"/>
                    <measurement group_id="O8" value="-10.9" spread="34.41"/>
                    <measurement group_id="O9" value="-11.5" spread="25.21"/>
                    <measurement group_id="O10" value="-4.7" spread="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16</title>
        <description>Fasting insulin levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline insulin value is the last non-missing value before the start of treatment. Change from Baseline in insulin was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Weeks 5, 8, 12, and 16</title>
          <description>Fasting insulin levels were measured after the participant had not eaten (fasted) for at least eight hours prior to the sampling. The Baseline insulin value is the last non-missing value before the start of treatment. Change from Baseline in insulin was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>Picomoles per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5, n=47,31,32,33,27,28,31,30,33,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="106.67"/>
                    <measurement group_id="O2" value="29.6" spread="104.29"/>
                    <measurement group_id="O3" value="-12.4" spread="72.90"/>
                    <measurement group_id="O4" value="-16.4" spread="114.61"/>
                    <measurement group_id="O5" value="0.4" spread="75.97"/>
                    <measurement group_id="O6" value="28.5" spread="99.26"/>
                    <measurement group_id="O7" value="-38.3" spread="104.22"/>
                    <measurement group_id="O8" value="-8.4" spread="75.38"/>
                    <measurement group_id="O9" value="11.1" spread="97.92"/>
                    <measurement group_id="O10" value="36.2" spread="115.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=49,32,33,34,28,29,32,31,33,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="106.05"/>
                    <measurement group_id="O2" value="5.4" spread="52.47"/>
                    <measurement group_id="O3" value="-16.5" spread="64.88"/>
                    <measurement group_id="O4" value="-8.5" spread="116.41"/>
                    <measurement group_id="O5" value="2.4" spread="98.07"/>
                    <measurement group_id="O6" value="18.6" spread="102.92"/>
                    <measurement group_id="O7" value="-14.4" spread="104.76"/>
                    <measurement group_id="O8" value="-16.8" spread="84.12"/>
                    <measurement group_id="O9" value="12.9" spread="92.97"/>
                    <measurement group_id="O10" value="6.6" spread="62.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=49,32,33,34,28,29,32,31,33,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="79.93"/>
                    <measurement group_id="O2" value="18.0" spread="60.31"/>
                    <measurement group_id="O3" value="-12.4" spread="67.03"/>
                    <measurement group_id="O4" value="-7.9" spread="106.19"/>
                    <measurement group_id="O5" value="-1.1" spread="86.02"/>
                    <measurement group_id="O6" value="17.8" spread="99.18"/>
                    <measurement group_id="O7" value="-26.1" spread="94.10"/>
                    <measurement group_id="O8" value="0.2" spread="90.27"/>
                    <measurement group_id="O9" value="38.0" spread="158.33"/>
                    <measurement group_id="O10" value="11.6" spread="73.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=49,32,33,34,28,29,32,31,33,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="42.74"/>
                    <measurement group_id="O2" value="17.4" spread="52.62"/>
                    <measurement group_id="O3" value="2.9" spread="81.64"/>
                    <measurement group_id="O4" value="-19.9" spread="112.32"/>
                    <measurement group_id="O5" value="25.1" spread="114.95"/>
                    <measurement group_id="O6" value="21.9" spread="99.41"/>
                    <measurement group_id="O7" value="-24.0" spread="90.05"/>
                    <measurement group_id="O8" value="-17.4" spread="80.04"/>
                    <measurement group_id="O9" value="12.9" spread="72.22"/>
                    <measurement group_id="O10" value="18.4" spread="80.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16</title>
        <description>Serum lipid components, including triglycerides (TG), free fatty acids (FFA), total cholesterol (CL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), were measured at Baseline and Weeks 5, 8, 12, and 16. The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
        <time_frame>Baseline and Weeks 5, 8, 12, and 16</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides, Free Fatty Acids, Total Cholesterol, Low-density Lipoprotein Cholesterol, and High-density Lipoprotein Cholesterol at Weeks 5, 8, 12, and 16</title>
          <description>Serum lipid components, including triglycerides (TG), free fatty acids (FFA), total cholesterol (CL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), were measured at Baseline and Weeks 5, 8, 12, and 16. The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="35"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TG, Week 5, n=45,31,34,31,27,29,31,34,35,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.225" spread="1.0354"/>
                    <measurement group_id="O2" value="-0.068" spread="0.7288"/>
                    <measurement group_id="O3" value="0.303" spread="2.1539"/>
                    <measurement group_id="O4" value="-0.376" spread="1.1387"/>
                    <measurement group_id="O5" value="0.112" spread="0.6974"/>
                    <measurement group_id="O6" value="-0.266" spread="1.2296"/>
                    <measurement group_id="O7" value="-0.147" spread="1.0251"/>
                    <measurement group_id="O8" value="-1.423" spread="3.7638"/>
                    <measurement group_id="O9" value="-0.725" spread="1.3749"/>
                    <measurement group_id="O10" value="-0.184" spread="0.5912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG, Week 8, n=50,33,34,34,27,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.222" spread="1.5590"/>
                    <measurement group_id="O2" value="-0.238" spread="0.6205"/>
                    <measurement group_id="O3" value="0.178" spread="2.1883"/>
                    <measurement group_id="O4" value="-0.408" spread="1.3143"/>
                    <measurement group_id="O5" value="-0.009" spread="0.6977"/>
                    <measurement group_id="O6" value="-0.219" spread="1.0210"/>
                    <measurement group_id="O7" value="-0.150" spread="0.9610"/>
                    <measurement group_id="O8" value="-1.494" spread="3.8212"/>
                    <measurement group_id="O9" value="-0.175" spread="1.6289"/>
                    <measurement group_id="O10" value="-0.028" spread="1.1012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG, Week 12, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.329" spread="1.2941"/>
                    <measurement group_id="O2" value="0.094" spread="1.4597"/>
                    <measurement group_id="O3" value="0.221" spread="2.3056"/>
                    <measurement group_id="O4" value="-0.341" spread="1.2139"/>
                    <measurement group_id="O5" value="0.106" spread="0.8936"/>
                    <measurement group_id="O6" value="-0.380" spread="0.8947"/>
                    <measurement group_id="O7" value="-0.269" spread="1.0358"/>
                    <measurement group_id="O8" value="-1.539" spread="3.9093"/>
                    <measurement group_id="O9" value="-0.362" spread="1.5880"/>
                    <measurement group_id="O10" value="0.070" spread="0.8288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG, Week 16, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.377" spread="1.6534"/>
                    <measurement group_id="O2" value="-0.149" spread="0.8423"/>
                    <measurement group_id="O3" value="0.122" spread="2.1274"/>
                    <measurement group_id="O4" value="-0.296" spread="1.2876"/>
                    <measurement group_id="O5" value="0.099" spread="0.9002"/>
                    <measurement group_id="O6" value="-0.258" spread="0.9248"/>
                    <measurement group_id="O7" value="-0.331" spread="0.9529"/>
                    <measurement group_id="O8" value="-1.469" spread="3.8476"/>
                    <measurement group_id="O9" value="-0.426" spread="1.7338"/>
                    <measurement group_id="O10" value="-0.114" spread="1.1446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA, Week 5, n=48,33,32,33,27,28,32,34,35,29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.1867"/>
                    <measurement group_id="O2" value="-0.038" spread="0.2518"/>
                    <measurement group_id="O3" value="-0.032" spread="0.1691"/>
                    <measurement group_id="O4" value="-0.008" spread="0.1392"/>
                    <measurement group_id="O5" value="0.014" spread="0.1381"/>
                    <measurement group_id="O6" value="0.025" spread="0.1927"/>
                    <measurement group_id="O7" value="-0.028" spread="0.2017"/>
                    <measurement group_id="O8" value="-0.012" spread="0.2266"/>
                    <measurement group_id="O9" value="-0.001" spread="0.1568"/>
                    <measurement group_id="O10" value="0.006" spread="0.2237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA, Week 8, n=50,34,33,34,28,29,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.2021"/>
                    <measurement group_id="O2" value="-0.045" spread="0.2186"/>
                    <measurement group_id="O3" value="0.033" spread="0.1699"/>
                    <measurement group_id="O4" value="-0.048" spread="0.1345"/>
                    <measurement group_id="O5" value="0.046" spread="0.1934"/>
                    <measurement group_id="O6" value="0.017" spread="0.1897"/>
                    <measurement group_id="O7" value="-0.027" spread="0.1974"/>
                    <measurement group_id="O8" value="-0.004" spread="0.2359"/>
                    <measurement group_id="O9" value="0.055" spread="0.1843"/>
                    <measurement group_id="O10" value="0.175" spread="0.8591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA, Week 12, n=50,34,33,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.2018"/>
                    <measurement group_id="O2" value="-0.007" spread="0.1882"/>
                    <measurement group_id="O3" value="0.022" spread="0.2003"/>
                    <measurement group_id="O4" value="-0.013" spread="0.1870"/>
                    <measurement group_id="O5" value="0.043" spread="0.1826"/>
                    <measurement group_id="O6" value="0.010" spread="0.1920"/>
                    <measurement group_id="O7" value="-0.051" spread="0.2250"/>
                    <measurement group_id="O8" value="0.011" spread="0.2481"/>
                    <measurement group_id="O9" value="-0.030" spread="0.1796"/>
                    <measurement group_id="O10" value="0.123" spread="0.8347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA, Week 16, n=50,34,33,34,28,29,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" spread="0.2047"/>
                    <measurement group_id="O2" value="-0.031" spread="0.1631"/>
                    <measurement group_id="O3" value="0.020" spread="0.2084"/>
                    <measurement group_id="O4" value="0.016" spread="0.2159"/>
                    <measurement group_id="O5" value="0.050" spread="0.1695"/>
                    <measurement group_id="O6" value="0.034" spread="0.2006"/>
                    <measurement group_id="O7" value="-0.005" spread="0.2494"/>
                    <measurement group_id="O8" value="0.025" spread="0.2319"/>
                    <measurement group_id="O9" value="0.012" spread="0.2065"/>
                    <measurement group_id="O10" value="0.094" spread="0.8399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total CL, Week 5, n=45,31,34,31,27,29,31,34,35,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.6128"/>
                    <measurement group_id="O2" value="-0.239" spread="0.6613"/>
                    <measurement group_id="O3" value="-0.153" spread="0.8765"/>
                    <measurement group_id="O4" value="-0.139" spread="0.5795"/>
                    <measurement group_id="O5" value="-0.113" spread="0.6588"/>
                    <measurement group_id="O6" value="-0.372" spread="0.6998"/>
                    <measurement group_id="O7" value="-0.140" spread="0.4168"/>
                    <measurement group_id="O8" value="-0.451" spread="0.9158"/>
                    <measurement group_id="O9" value="-0.407" spread="0.6393"/>
                    <measurement group_id="O10" value="-0.245" spread="0.5284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total CL, Week 8, n=50,33,34,34,27,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" spread="0.5932"/>
                    <measurement group_id="O2" value="-0.182" spread="0.6517"/>
                    <measurement group_id="O3" value="-0.060" spread="0.9192"/>
                    <measurement group_id="O4" value="-0.162" spread="0.4772"/>
                    <measurement group_id="O5" value="0.002" spread="0.5870"/>
                    <measurement group_id="O6" value="-0.172" spread="0.6633"/>
                    <measurement group_id="O7" value="-0.094" spread="0.4566"/>
                    <measurement group_id="O8" value="-0.418" spread="0.8572"/>
                    <measurement group_id="O9" value="-0.183" spread="0.8011"/>
                    <measurement group_id="O10" value="0.060" spread="0.6296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total CL, Week 12, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.6465"/>
                    <measurement group_id="O2" value="0.054" spread="0.7723"/>
                    <measurement group_id="O3" value="-0.025" spread="0.9136"/>
                    <measurement group_id="O4" value="-0.140" spread="0.5686"/>
                    <measurement group_id="O5" value="-0.020" spread="0.6926"/>
                    <measurement group_id="O6" value="-0.190" spread="0.5975"/>
                    <measurement group_id="O7" value="-0.092" spread="0.8249"/>
                    <measurement group_id="O8" value="-0.338" spread="0.9449"/>
                    <measurement group_id="O9" value="-0.134" spread="0.6620"/>
                    <measurement group_id="O10" value="0.015" spread="0.5786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total CL, Week 16, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.7695"/>
                    <measurement group_id="O2" value="-0.031" spread="0.8271"/>
                    <measurement group_id="O3" value="-0.032" spread="0.9312"/>
                    <measurement group_id="O4" value="-0.037" spread="0.5402"/>
                    <measurement group_id="O5" value="0.009" spread="0.5964"/>
                    <measurement group_id="O6" value="-0.225" spread="0.5420"/>
                    <measurement group_id="O7" value="-0.178" spread="0.4476"/>
                    <measurement group_id="O8" value="-0.447" spread="0.8464"/>
                    <measurement group_id="O9" value="-0.217" spread="0.7376"/>
                    <measurement group_id="O10" value="0.018" spread="0.5532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 5, n=41,29,31,29,26,28,29,27,32,29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.5417"/>
                    <measurement group_id="O2" value="-0.153" spread="0.5479"/>
                    <measurement group_id="O3" value="-0.294" spread="0.7053"/>
                    <measurement group_id="O4" value="-0.155" spread="0.5653"/>
                    <measurement group_id="O5" value="-0.068" spread="0.6225"/>
                    <measurement group_id="O6" value="-0.285" spread="0.5345"/>
                    <measurement group_id="O7" value="-0.082" spread="0.3708"/>
                    <measurement group_id="O8" value="0.026" spread="0.5064"/>
                    <measurement group_id="O9" value="-0.106" spread="0.4576"/>
                    <measurement group_id="O10" value="-0.091" spread="0.4910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 8, n=45,32,32,32,26,30,31,28,32,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.5123"/>
                    <measurement group_id="O2" value="-0.014" spread="0.5556"/>
                    <measurement group_id="O3" value="-0.132" spread="0.7398"/>
                    <measurement group_id="O4" value="-0.157" spread="0.5620"/>
                    <measurement group_id="O5" value="0.089" spread="0.6053"/>
                    <measurement group_id="O6" value="-0.160" spread="0.5305"/>
                    <measurement group_id="O7" value="-0.052" spread="0.4403"/>
                    <measurement group_id="O8" value="0.053" spread="0.4543"/>
                    <measurement group_id="O9" value="-0.087" spread="0.4336"/>
                    <measurement group_id="O10" value="0.054" spread="0.5581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 12, n=45,33,32,32,28,30,31,28,32,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138" spread="0.4923"/>
                    <measurement group_id="O2" value="0.105" spread="0.6259"/>
                    <measurement group_id="O3" value="-0.096" spread="0.6483"/>
                    <measurement group_id="O4" value="-0.152" spread="0.6477"/>
                    <measurement group_id="O5" value="0.004" spread="0.6456"/>
                    <measurement group_id="O6" value="-0.034" spread="0.5547"/>
                    <measurement group_id="O7" value="-0.004" spread="0.7153"/>
                    <measurement group_id="O8" value="0.156" spread="0.4614"/>
                    <measurement group_id="O9" value="-0.061" spread="0.3790"/>
                    <measurement group_id="O10" value="0.010" spread="0.4771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 16, n=46,33,32,32,28,30,31,28,32,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" spread="0.6025"/>
                    <measurement group_id="O2" value="0.096" spread="0.6960"/>
                    <measurement group_id="O3" value="-0.109" spread="0.6558"/>
                    <measurement group_id="O4" value="-0.045" spread="0.6183"/>
                    <measurement group_id="O5" value="0.003" spread="0.6010"/>
                    <measurement group_id="O6" value="-0.123" spread="0.5198"/>
                    <measurement group_id="O7" value="-0.062" spread="0.3943"/>
                    <measurement group_id="O8" value="0.059" spread="0.5750"/>
                    <measurement group_id="O9" value="-0.088" spread="0.5125"/>
                    <measurement group_id="O10" value="0.054" spread="0.4475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 5, n=45,31,34,31,27,29,31,34,35,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.1189"/>
                    <measurement group_id="O2" value="-0.047" spread="0.1420"/>
                    <measurement group_id="O3" value="0.001" spread="0.1203"/>
                    <measurement group_id="O4" value="-0.010" spread="0.1491"/>
                    <measurement group_id="O5" value="-0.063" spread="0.1425"/>
                    <measurement group_id="O6" value="-0.038" spread="0.1215"/>
                    <measurement group_id="O7" value="-0.045" spread="0.1434"/>
                    <measurement group_id="O8" value="-0.076" spread="0.1553"/>
                    <measurement group_id="O9" value="-0.047" spread="0.1765"/>
                    <measurement group_id="O10" value="-0.053" spread="0.1129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 8, n=50,33,34,34,27,30,32,34,35,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.1192"/>
                    <measurement group_id="O2" value="-0.058" spread="0.1606"/>
                    <measurement group_id="O3" value="0.006" spread="0.1160"/>
                    <measurement group_id="O4" value="0.019" spread="0.1187"/>
                    <measurement group_id="O5" value="-0.061" spread="0.1368"/>
                    <measurement group_id="O6" value="-0.018" spread="0.1417"/>
                    <measurement group_id="O7" value="-0.030" spread="0.1217"/>
                    <measurement group_id="O8" value="-0.050" spread="0.1403"/>
                    <measurement group_id="O9" value="-0.054" spread="0.1746"/>
                    <measurement group_id="O10" value="-0.016" spread="0.1567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 12, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.1341"/>
                    <measurement group_id="O2" value="-0.003" spread="0.2269"/>
                    <measurement group_id="O3" value="0.004" spread="0.1258"/>
                    <measurement group_id="O4" value="-0.019" spread="0.1115"/>
                    <measurement group_id="O5" value="-0.061" spread="0.1674"/>
                    <measurement group_id="O6" value="-0.018" spread="0.1323"/>
                    <measurement group_id="O7" value="-0.041" spread="0.1998"/>
                    <measurement group_id="O8" value="-0.029" spread="0.1303"/>
                    <measurement group_id="O9" value="-0.033" spread="0.1445"/>
                    <measurement group_id="O10" value="-0.045" spread="0.1411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 16, n=50,34,34,34,28,30,32,34,35,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.1274"/>
                    <measurement group_id="O2" value="-0.025" spread="0.2192"/>
                    <measurement group_id="O3" value="-0.007" spread="0.1366"/>
                    <measurement group_id="O4" value="-0.010" spread="0.1342"/>
                    <measurement group_id="O5" value="-0.046" spread="0.1699"/>
                    <measurement group_id="O6" value="-0.015" spread="0.1146"/>
                    <measurement group_id="O7" value="-0.031" spread="0.1413"/>
                    <measurement group_id="O8" value="-0.065" spread="0.1730"/>
                    <measurement group_id="O9" value="-0.033" spread="0.1595"/>
                    <measurement group_id="O10" value="-0.048" spread="0.1930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Living Index – Emesis (FLIE) Scores at Week 16</title>
        <description>The FLIE questionnaire is used to record the participant's feelings/opinions concerning the effects of nausea/vomiting on their quality of life during the past five days. Participants completed the questionnaire by responding to 18 questions. The first set of 9 questions refer to nausea, and the second set of 9 questions refer to vomiting. Each question is scored on a seven-point visual analog scale (1 to 7). On this scale, a score of 1 corresponds to 0 millimeters (mm), and a score of 7 correspond to 100 mm. Anything in between is marked at the appropriate point on the scale and is measured in mm. Data are reported in mm in this table. In FLIE questions (FLIEQ) 1, 2, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, and 17, a score of 1 indicates no effect on the quality of life, and a score of 7 indicates a great effect on the quality of life. In FLIEQ 3, 6, 11, 15, and 18, a score of 1 indicates a great effect on the quality of life, and a score of 7 indicates no effect on the quality of life.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Safety Population: all randomly assigned participants who received at least one dose of study drug. Only those participants available at the specified time point were analyzed. Change from Baseline was calculated as the score at Week 16 minus the score at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Living Index – Emesis (FLIE) Scores at Week 16</title>
          <description>The FLIE questionnaire is used to record the participant's feelings/opinions concerning the effects of nausea/vomiting on their quality of life during the past five days. Participants completed the questionnaire by responding to 18 questions. The first set of 9 questions refer to nausea, and the second set of 9 questions refer to vomiting. Each question is scored on a seven-point visual analog scale (1 to 7). On this scale, a score of 1 corresponds to 0 millimeters (mm), and a score of 7 correspond to 100 mm. Anything in between is marked at the appropriate point on the scale and is measured in mm. Data are reported in mm in this table. In FLIE questions (FLIEQ) 1, 2, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, and 17, a score of 1 indicates no effect on the quality of life, and a score of 7 indicates a great effect on the quality of life. In FLIEQ 3, 6, 11, 15, and 18, a score of 1 indicates a great effect on the quality of life, and a score of 7 indicates no effect on the quality of life.</description>
          <population>Safety Population: all randomly assigned participants who received at least one dose of study drug. Only those participants available at the specified time point were analyzed. Change from Baseline was calculated as the score at Week 16 minus the score at Baseline.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FLIEQ1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="6.79"/>
                    <measurement group_id="O2" value="-4.4" spread="19.25"/>
                    <measurement group_id="O3" value="5.7" spread="23.42"/>
                    <measurement group_id="O4" value="1.0" spread="19.54"/>
                    <measurement group_id="O5" value="4.6" spread="11.35"/>
                    <measurement group_id="O6" value="8.6" spread="24.35"/>
                    <measurement group_id="O7" value="-1.0" spread="2.22"/>
                    <measurement group_id="O8" value="8.2" spread="22.66"/>
                    <measurement group_id="O9" value="-0.3" spread="7.18"/>
                    <measurement group_id="O10" value="-2.8" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.15"/>
                    <measurement group_id="O2" value="-3.5" spread="18.64"/>
                    <measurement group_id="O3" value="5.5" spread="23.42"/>
                    <measurement group_id="O4" value="2.6" spread="18.20"/>
                    <measurement group_id="O5" value="3.0" spread="11.67"/>
                    <measurement group_id="O6" value="5.9" spread="22.87"/>
                    <measurement group_id="O7" value="-0.8" spread="4.03"/>
                    <measurement group_id="O8" value="4.7" spread="21.95"/>
                    <measurement group_id="O9" value="-0.6" spread="3.21"/>
                    <measurement group_id="O10" value="-0.2" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="36.34"/>
                    <measurement group_id="O2" value="7.8" spread="25.52"/>
                    <measurement group_id="O3" value="10.3" spread="42.11"/>
                    <measurement group_id="O4" value="-4.0" spread="19.64"/>
                    <measurement group_id="O5" value="18.6" spread="47.37"/>
                    <measurement group_id="O6" value="10.3" spread="45.34"/>
                    <measurement group_id="O7" value="3.9" spread="32.47"/>
                    <measurement group_id="O8" value="18.2" spread="39.83"/>
                    <measurement group_id="O9" value="4.5" spread="28.67"/>
                    <measurement group_id="O10" value="7.3" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.06"/>
                    <measurement group_id="O2" value="-3.5" spread="18.32"/>
                    <measurement group_id="O3" value="6.4" spread="24.11"/>
                    <measurement group_id="O4" value="-2.8" spread="11.95"/>
                    <measurement group_id="O5" value="1.5" spread="5.16"/>
                    <measurement group_id="O6" value="5.6" spread="22.91"/>
                    <measurement group_id="O7" value="-1.6" spread="8.84"/>
                    <measurement group_id="O8" value="5.9" spread="22.48"/>
                    <measurement group_id="O9" value="-1.9" spread="16.90"/>
                    <measurement group_id="O10" value="-1.8" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.46"/>
                    <measurement group_id="O2" value="-4.0" spread="18.21"/>
                    <measurement group_id="O3" value="6.4" spread="23.09"/>
                    <measurement group_id="O4" value="-1.8" spread="7.18"/>
                    <measurement group_id="O5" value="2.9" spread="11.23"/>
                    <measurement group_id="O6" value="0.2" spread="33.34"/>
                    <measurement group_id="O7" value="-1.3" spread="5.41"/>
                    <measurement group_id="O8" value="4.5" spread="21.97"/>
                    <measurement group_id="O9" value="1.5" spread="6.42"/>
                    <measurement group_id="O10" value="-1.4" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="38.64"/>
                    <measurement group_id="O2" value="3.6" spread="29.76"/>
                    <measurement group_id="O3" value="9.4" spread="40.77"/>
                    <measurement group_id="O4" value="-0.5" spread="26.11"/>
                    <measurement group_id="O5" value="20.0" spread="44.44"/>
                    <measurement group_id="O6" value="10.2" spread="45.38"/>
                    <measurement group_id="O7" value="4.2" spread="31.38"/>
                    <measurement group_id="O8" value="18.0" spread="40.06"/>
                    <measurement group_id="O9" value="5.6" spread="26.54"/>
                    <measurement group_id="O10" value="3.9" spread="36.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.20"/>
                    <measurement group_id="O2" value="-3.1" spread="19.16"/>
                    <measurement group_id="O3" value="5.7" spread="23.46"/>
                    <measurement group_id="O4" value="1.5" spread="16.77"/>
                    <measurement group_id="O5" value="0.2" spread="0.69"/>
                    <measurement group_id="O6" value="5.7" spread="22.88"/>
                    <measurement group_id="O7" value="-1.0" spread="6.71"/>
                    <measurement group_id="O8" value="4.9" spread="21.93"/>
                    <measurement group_id="O9" value="-0.1" spread="4.85"/>
                    <measurement group_id="O10" value="-1.9" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="4.46"/>
                    <measurement group_id="O2" value="-3.5" spread="18.60"/>
                    <measurement group_id="O3" value="5.7" spread="23.36"/>
                    <measurement group_id="O4" value="-1.0" spread="10.95"/>
                    <measurement group_id="O5" value="2.6" spread="9.80"/>
                    <measurement group_id="O6" value="10.1" spread="29.33"/>
                    <measurement group_id="O7" value="-0.7" spread="3.14"/>
                    <measurement group_id="O8" value="6.2" spread="22.05"/>
                    <measurement group_id="O9" value="-0.4" spread="4.91"/>
                    <measurement group_id="O10" value="-2.3" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.55"/>
                    <measurement group_id="O2" value="-3.4" spread="17.86"/>
                    <measurement group_id="O3" value="5.3" spread="23.45"/>
                    <measurement group_id="O4" value="-0.5" spread="3.64"/>
                    <measurement group_id="O5" value="2.3" spread="8.70"/>
                    <measurement group_id="O6" value="5.6" spread="22.91"/>
                    <measurement group_id="O7" value="-0.7" spread="3.20"/>
                    <measurement group_id="O8" value="4.0" spread="22.33"/>
                    <measurement group_id="O9" value="-0.1" spread="4.63"/>
                    <measurement group_id="O10" value="-3.2" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.27"/>
                    <measurement group_id="O2" value="-4.9" spread="18.81"/>
                    <measurement group_id="O3" value="5.8" spread="22.70"/>
                    <measurement group_id="O4" value="-1.6" spread="6.51"/>
                    <measurement group_id="O5" value="-0.1" spread="3.55"/>
                    <measurement group_id="O6" value="4.5" spread="23.37"/>
                    <measurement group_id="O7" value="-0.3" spread="1.81"/>
                    <measurement group_id="O8" value="4.3" spread="22.00"/>
                    <measurement group_id="O9" value="0.2" spread="1.90"/>
                    <measurement group_id="O10" value="-2.0" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="36.17"/>
                    <measurement group_id="O2" value="3.3" spread="30.36"/>
                    <measurement group_id="O3" value="13.8" spread="34.10"/>
                    <measurement group_id="O4" value="-0.5" spread="38.39"/>
                    <measurement group_id="O5" value="21.9" spread="42.11"/>
                    <measurement group_id="O6" value="7.9" spread="46.96"/>
                    <measurement group_id="O7" value="3.6" spread="19.32"/>
                    <measurement group_id="O8" value="18.3" spread="40.27"/>
                    <measurement group_id="O9" value="7.2" spread="25.77"/>
                    <measurement group_id="O10" value="4.0" spread="36.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.52"/>
                    <measurement group_id="O2" value="-3.1" spread="17.45"/>
                    <measurement group_id="O3" value="6.4" spread="23.00"/>
                    <measurement group_id="O4" value="-0.8" spread="8.09"/>
                    <measurement group_id="O5" value="1.8" spread="6.40"/>
                    <measurement group_id="O6" value="5.3" spread="22.95"/>
                    <measurement group_id="O7" value="-0.2" spread="2.26"/>
                    <measurement group_id="O8" value="4.4" spread="21.97"/>
                    <measurement group_id="O9" value="-0.4" spread="3.17"/>
                    <measurement group_id="O10" value="-0.8" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.57"/>
                    <measurement group_id="O2" value="-4.0" spread="18.31"/>
                    <measurement group_id="O3" value="6.3" spread="23.03"/>
                    <measurement group_id="O4" value="-2.2" spread="8.43"/>
                    <measurement group_id="O5" value="1.0" spread="6.12"/>
                    <measurement group_id="O6" value="9.8" spread="29.41"/>
                    <measurement group_id="O7" value="-0.3" spread="1.71"/>
                    <measurement group_id="O8" value="4.3" spread="22.02"/>
                    <measurement group_id="O9" value="0.0" spread="1.72"/>
                    <measurement group_id="O10" value="-2.1" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.95"/>
                    <measurement group_id="O2" value="-4.1" spread="18.18"/>
                    <measurement group_id="O3" value="6.4" spread="23.12"/>
                    <measurement group_id="O4" value="-1.4" spread="6.22"/>
                    <measurement group_id="O5" value="1.8" spread="6.15"/>
                    <measurement group_id="O6" value="5.3" spread="22.94"/>
                    <measurement group_id="O7" value="-0.1" spread="1.61"/>
                    <measurement group_id="O8" value="4.3" spread="22.0"/>
                    <measurement group_id="O9" value="-0.1" spread="1.81"/>
                    <measurement group_id="O10" value="-2.1" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="36.06"/>
                    <measurement group_id="O2" value="7.0" spread="23.57"/>
                    <measurement group_id="O3" value="14.2" spread="34.03"/>
                    <measurement group_id="O4" value="-4.9" spread="18.87"/>
                    <measurement group_id="O5" value="19.7" spread="46.48"/>
                    <measurement group_id="O6" value="5.6" spread="50.36"/>
                    <measurement group_id="O7" value="3.5" spread="19.32"/>
                    <measurement group_id="O8" value="18.4" spread="40.22"/>
                    <measurement group_id="O9" value="1.5" spread="20.48"/>
                    <measurement group_id="O10" value="4.0" spread="36.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.58"/>
                    <measurement group_id="O2" value="-3.8" spread="18.20"/>
                    <measurement group_id="O3" value="6.3" spread="23.02"/>
                    <measurement group_id="O4" value="-1.4" spread="7.37"/>
                    <measurement group_id="O5" value="-0.5" spread="3.66"/>
                    <measurement group_id="O6" value="8.2" spread="25.92"/>
                    <measurement group_id="O7" value="-0.1" spread="1.80"/>
                    <measurement group_id="O8" value="4.5" spread="21.95"/>
                    <measurement group_id="O9" value="0.9" spread="5.55"/>
                    <measurement group_id="O10" value="-1.5" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.60"/>
                    <measurement group_id="O2" value="-4.1" spread="18.14"/>
                    <measurement group_id="O3" value="6.3" spread="22.97"/>
                    <measurement group_id="O4" value="-1.2" spread="6.08"/>
                    <measurement group_id="O5" value="-1.2" spread="5.10"/>
                    <measurement group_id="O6" value="4.5" spread="23.36"/>
                    <measurement group_id="O7" value="-0.2" spread="1.98"/>
                    <measurement group_id="O8" value="4.3" spread="22.02"/>
                    <measurement group_id="O9" value="-1.1" spread="5.62"/>
                    <measurement group_id="O10" value="-0.6" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIEQ18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="37.82"/>
                    <measurement group_id="O2" value="6.9" spread="23.47"/>
                    <measurement group_id="O3" value="14.2" spread="33.91"/>
                    <measurement group_id="O4" value="-3.2" spread="17.62"/>
                    <measurement group_id="O5" value="14.9" spread="34.45"/>
                    <measurement group_id="O6" value="10.1" spread="45.39"/>
                    <measurement group_id="O7" value="7.1" spread="26.96"/>
                    <measurement group_id="O8" value="18.5" spread="40.09"/>
                    <measurement group_id="O9" value="5.7" spread="26.48"/>
                    <measurement group_id="O10" value="6.9" spread="30.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16</title>
        <description>The HCFQ questionnaire is used to record how often participants have felt hungry or craved food, and how full participants felt after finishing meals, on average, in the past week. Participants answered the following seven questions with the response that best described their feelings of hunger, craving, and fullness: Q1, &quot;In the past week I was hungry&quot;; Q2, &quot;In the past week I thought about food&quot;; Q3, &quot;In the past week I wanted to eat&quot;; Q4, &quot;In the past week I ate more than I should have&quot;; Q5, &quot;In the past week, I craved specific food&quot;; Q6, &quot;In the past week when finished meals I felt full&quot;; Q7, &quot;In the past week when finished meals I felt satisfied.&quot;</description>
        <time_frame>Week 16</time_frame>
        <population>Safety Population. Only those participants available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide BID</title>
            <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
          </group>
          <group group_id="O3">
            <title>Albiglutide 4 mg Weekly</title>
            <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O4">
            <title>Albiglutide 15 mg Weekly</title>
            <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O5">
            <title>Albiglutide 30 mg Weekly</title>
            <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O6">
            <title>Albiglutide 15 mg Bi-weekly</title>
            <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O7">
            <title>Albiglutide 30 mg Bi-weekly</title>
            <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O8">
            <title>Albiglutide 50 mg Bi-weekly</title>
            <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O9">
            <title>Albiglutide 50 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
          <group group_id="O10">
            <title>Albiglutide 100 mg Every 4 Weeks</title>
            <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Response to Questions on the Hunger, Craving, and Fullness Questionnaire (HCFQ) at Week 16</title>
          <description>The HCFQ questionnaire is used to record how often participants have felt hungry or craved food, and how full participants felt after finishing meals, on average, in the past week. Participants answered the following seven questions with the response that best described their feelings of hunger, craving, and fullness: Q1, &quot;In the past week I was hungry&quot;; Q2, &quot;In the past week I thought about food&quot;; Q3, &quot;In the past week I wanted to eat&quot;; Q4, &quot;In the past week I ate more than I should have&quot;; Q5, &quot;In the past week, I craved specific food&quot;; Q6, &quot;In the past week when finished meals I felt full&quot;; Q7, &quot;In the past week when finished meals I felt satisfied.&quot;</description>
          <population>Safety Population. Only those participants available at the specified time point were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1: Always</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1: Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1: Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1: Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1: Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Always</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3: Always</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3: Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3: Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3: Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3: Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4: Yes, definitely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4: Yes, probably</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4: I don't know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4: Probably not</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4: Definitely not</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5: Always</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5: Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5: Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5: Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5: Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6: Much too full</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6: Very full</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6: Comfortably full</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6: Slightly hungry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6: Very hungry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7: Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7: Neither satisfied nor dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7: Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7: Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Clearance of Albiglutide</title>
        <description>Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose pharmacokinetic (PK) sampling was performed within 6 days of drug administration.</description>
        <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
        <population>PK Analysis Population: all participants for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Receiving Any Dose of Albiglutide</title>
            <description>Participants received one of the following doses of albiglutide: 4 mg weekly, 15 mg weekly, 30 mg weekly (administered as a subcutaneous injection for 16 weeks) ; 15 mg bi-weekly, 30 mg bi-weekly, 50 mg bi-weekly (alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks); 50 mg every 4 weeks, 100 mg every 4 weeks (administered as a subcutaneous injection for 16 weeks). Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clearance of Albiglutide</title>
          <description>Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose pharmacokinetic (PK) sampling was performed within 6 days of drug administration.</description>
          <population>PK Analysis Population: all participants for whom a PK sample was obtained and analyzed</population>
          <units>milliliters per hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="90.1" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Volume of Distribution of Albiglutide</title>
        <description>Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
        <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
        <population>PK Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Receiving Any Dose of Albiglutide</title>
            <description>Participants received one of the following doses of albiglutide: 4 mg weekly, 15 mg weekly, 30 mg weekly (administered as a subcutaneous injection for 16 weeks) ; 15 mg bi-weekly, 30 mg bi-weekly, 50 mg bi-weekly (alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks); 50 mg every 4 weeks, 100 mg every 4 weeks (administered as a subcutaneous injection for 16 weeks). Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Volume of Distribution of Albiglutide</title>
          <description>Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
          <population>PK Analysis Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16400" lower_limit="15600" upper_limit="17300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absorption Rate of Albiglutide</title>
        <description>Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
        <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
        <population>PK Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Receiving Any Dose of Albiglutide</title>
            <description>Participants received one of the following doses of albiglutide: 4 mg weekly, 15 mg weekly, 30 mg weekly (administered as a subcutaneous injection for 16 weeks) ; 15 mg bi-weekly, 30 mg bi-weekly, 50 mg bi-weekly (alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks); 50 mg every 4 weeks, 100 mg every 4 weeks (administered as a subcutaneous injection for 16 weeks). Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absorption Rate of Albiglutide</title>
          <description>Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration.</description>
          <population>PK Analysis Population</population>
          <units>hour^-1</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0193" lower_limit="0.017" upper_limit="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG</title>
        <description>EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model.</description>
        <time_frame>Weeks 0, 4, 5, 7, 8, 9, 12, 15, 16, 17 18, 20, 23, and 27</time_frame>
        <population>PK/PD Analysis Population: all participants in the PK Analysis Population with sufficient dosing history for inclusion in the PK/PD analysis</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Receiving Any Dose of Albiglutide</title>
            <description>Participants received one of the following doses of albiglutide: 4 mg weekly, 15 mg weekly, 30 mg weekly (administered as a subcutaneous injection for 16 weeks) ; 15 mg bi-weekly, 30 mg bi-weekly, 50 mg bi-weekly (alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks); 50 mg every 4 weeks, 100 mg every 4 weeks (administered as a subcutaneous injection for 16 weeks). Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG</title>
          <description>EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 4, 5, 7, 8, 9, 12, 15) and on the day of the clinic visit at Weeks 16, 17, 18, 20, 23, and 27. The Week 5, 8, and 12 post-dose (PK sampling was performed within 6 days of drug administration. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model.</description>
          <population>PK/PD Analysis Population: all participants in the PK Analysis Population with sufficient dosing history for inclusion in the PK/PD analysis</population>
          <units>nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c, Treatment-naïve group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1140" lower_limit="483" upper_limit="2990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c, Prior monotherapy group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230" lower_limit="403" upper_limit="3560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FPG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1970" lower_limit="950" upper_limit="5410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-therapy serious adverse events (SAEs) and non-serious AEs, defined as those that have a start date on or after the first day of study medication and within 56 days after the end of study medication, are reported.</time_frame>
      <desc>SAEs and non-serious AEs are reported for members of the Safety Population, comprised of all participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E2">
          <title>Exenatide BID</title>
          <description>Participants self-administered exenatide as a subcutaneous injection using prefilled pens, in accordance with current prescribing information. A dose of 5 micrograms (μg) was administered twice daily (BID) for the first 4 weeks, followed by a 12-week administration of a 10 μg BID dose. Participants who could not tolerate a 10 μg dose were to continue the study on the 5 μg BID dose.</description>
        </group>
        <group group_id="E3">
          <title>Albiglutide 4 mg Weekly</title>
          <description>Participants received albiglutide 4 milligrams (mg) weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E4">
          <title>Albiglutide 15 mg Weekly</title>
          <description>Participants received albiglutide 15 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E5">
          <title>Albiglutide 30 mg Weekly</title>
          <description>Participants received albiglutide 30 mg weekly, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E6">
          <title>Albiglutide 15 mg Bi-weekly</title>
          <description>Participants received albiglutide 15 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E7">
          <title>Albiglutide 30 mg Bi-weekly</title>
          <description>Participants received albiglutide 30 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E8">
          <title>Albiglutide 50 mg Bi-weekly</title>
          <description>Participants received albiglutide 50 mg every other week, alternating with placebo for each intervening week, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E9">
          <title>Albiglutide 50 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 50 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
        <group group_id="E10">
          <title>Albiglutide 100 mg Every 4 Weeks</title>
          <description>Participants received albiglutide 100 mg every 4 weeks, administered as a subcutaneous injection for 16 weeks. Participants received subcutaneous injections alternating between the left and right sides of the body.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="26" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

